One of the trials is evaluating the triplet combination of Telcyta, a tumor-activated drug candidate, with standard doses of carboplatin and paclitaxel in 35 patients with advanced stages of the disease. 58% of the patients showed an objective tumor response rate, while the disease stabilization rate was 92%.
Responses were observed at all doses of Telcyta and at all participating sites. Phase II enrollment in the trial has been increased to confirm the interim results for future clinical studies.
The second of the trials is testing Telcyta in combination with the standard dose of cisplatin in 49 patients with the same advanced state. Objective partial responses were observed in 32% of the patients and the disease stabilization rate was 88%.
In both studies the company said the regimen was generally well tolerated.